Ligand Reports Second Quarter 2017 Financial Results
Ligand to Report Second Quarter 2017 Results on August 7th
Ligand Enters Into Commercial License and Supply Agreement with Amgen for Rights to Use Captisol in the Formulation of AMG 330
Ligand’s Partner Melinta Therapeutics Announces U.S. FDA Approval of Baxdela™ (Delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Ligand Enters into Worldwide OmniAb® Platform License Agreement with Surface Oncology
Ligand Announces Aziyo Biologics Acquires Commercial Products from Partner CorMatrix
Ligand Enters Into Worldwide OmniAb® Platform License Agreement With xCella Biosciences
Ligand to Participate in Two Upcoming Investor Conferences
Ligand Reports First Quarter 2017 Financial Results
Ligand to Report First Quarter 2017 Results on May 9th
Ligand Enters Commercial License and Supply Agreements with Marinus Pharmaceuticals for Captisol-Enabled Ganaxolone
Ligand Announces Licensing Partner Janssen Has Filed an IND for an Antibody Discovered Using the OmniAb® Technology
Ligand to Participate in Upcoming Investor Conference
Ligand Provides Highlights from Today’s Analyst Day Event
